We are live on ! Find out more
CCM

Camber Capital Management Portfolio holdings

AUM $1.07B
1-Year Est. Return 8.19%
This Fund
S&P 500
This Quarter Est. Return
-3.44%
1 Year Est. Return
-8.19%
3 Year Est. Return
+26.6%
5 Year Est. Return
+54.57%
10 Year Est. Return
+164.72%
AUM
$1.06B
AUM Growth
-$462M
Cap. Flow
-$399M
Cap. Flow %
-37.47%
Top 10 Hldgs %
54.06%
Holding
50
New
9
Increased
12
Reduced
4
Closed
13

Top Buys

Rank Stock Value
1
GSK icon
GSK
GSK
+$58.9M
2
ESRX
Express Scripts Holding Company
ESRX
+$49.9M
3
VRTX icon
Vertex Pharmaceuticals
VRTX
+$38.1M
4
OFIX icon
Orthofix Medical
OFIX
+$36.2M
5
VOLC
VOLCANO CORPORATION COM STK
VOLC
+$26.3M

Top Sells

Rank Stock Value
1
ELV icon
Elevance Health
ELV
+$75.3M
2
CYH icon
Community Health Systems
CYH
+$63M
3
HCA icon
HCA Healthcare
HCA
+$50.7M
4
THC icon
Tenet Healthcare
THC
+$42.2M
5
LH icon
Labcorp
LH
+$41M

Sector Composition

Rank Sector Weight
1 Healthcare 71.35%
2 Consumer Discretionary 2.58%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
TEVA icon
1
Teva Pharmaceuticals
TEVA
$40.4B
$94.1M 8.84%
1,750,000
– –
VTRS icon
2
Viatris
VTRS
$20.8B
$63.7M 5.98%
1,400,000
+400,000
+40% +$19.4M
MASI
3
DELISTED
Masimo
MASI
$57.5M 5.4%
2,700,000
+880,000
+48% +$20.1M
GHDX
4
DELISTED
Genomic Health, Inc.
GHDX
$56.6M 5.32%
2,000,000
+275,000
+16% +$7.67M
GSK icon
5
GSK
GSK
$107B
$55.2M 5.18%
+960,000
New +$58.9M
VOLC
6
DELISTED
VOLCANO CORPORATION COM STK
VOLC
$53.7M 5.05%
5,050,000
+1,900,000
+60% +$26.3M
CNMD icon
7
CONMED
CNMD
$1.3B
$51M 4.79%
1,385,000
– –
ESRX
8
DELISTED
Express Scripts Holding Company
ESRX
$49.4M 4.65%
+700,000
New +$49.9M
KERX
9
DELISTED
Keryx Biopharmaceuticals Inc
KERX
$48.1M 4.52%
3,500,000
+500,000
+17% +$7.65M
GSK icon
10
CALL
GSK
GSK
$107B
$46M 4.32%
+800,000
New +$49M
VRTX icon
11
Vertex Pharmaceuticals
VRTX
$123B
$44.9M 4.22%
+400,000
New +$38.1M
OFIX icon
12
Orthofix Medical
OFIX
$492M
$37.5M 3.52%
1,210,164
+1,091,481
+920% +$36.2M
UAM
13
DELISTED
Universal American Corp
UAM
$33.6M 3.16%
4,178,259
– –
ACHN
14
DELISTED
Achillion Pharmaceuticals
ACHN
$32.4M 3.05%
3,250,000
-2,550,000
-44% -$23.7M
ARIA
15
DELISTED
Ariad Pharmaceuticals Inc
ARIA
$32.4M 3.04%
6,000,000
+1,000,000
+20% +$5.84M
DGX icon
16
Quest Diagnostics
DGX
$26B
$30.3M 2.85%
500,000
-600,000
-55% -$37M
WW
17
DELISTED
WW International
WW
$27.4M 2.58%
1,000,000
+150,000
+18% +$3.42M
TEVA icon
18
CALL
Teva Pharmaceuticals
TEVA
$40.4B
$26.9M 2.53%
500,000
– –
AMAG
19
DELISTED
AMAG Pharmaceuticals
AMAG
$23.9M 2.25%
+750,000
New +$16M
SQNM
20
DELISTED
SEQUENOM INC NEW
SQNM
$23.8M 2.23%
8,000,000
+1,700,000
+27% +$6.22M
NVAX icon
21
Novavax
NVAX
$1.21B
$19.8M 1.86%
237,500
– –
BRKR icon
22
Bruker
BRKR
$9.4B
$18.5M 1.74%
1,000,000
+500,000
+100% +$10.7M
ICUI icon
23
ICU Medical
ICUI
$4.16B
$17.8M 1.67%
277,583
– –
BRLI
24
DELISTED
BIO-REFERENCE LABS INC-NEW-
BRLI
$15.3M 1.43%
543,724
– –
WCG
25
DELISTED
Wellcare Health Plans, Inc.
WCG
$14.2M 1.33%
+235,174
New +$15.6M
1
2

Similar funds

PP
PrairieView Partners St. Paul, Minnesota $1.03B AUM 11.4% 1-Year Est. Return
SAF
Smith Anglin Financial Dallas, Texas $1.1B AUM 14.08% 1-Year Est. Return
NRD
Nebula Research & Development New York $1.17B AUM 15.19% 1-Year Est. Return
FC
Forte Capital Rochester, New York $930M AUM 24.11% 1-Year Est. Return
GIM
Grassi Investment Management Santa Clara, California $1.26B AUM 23.4% 1-Year Est. Return
SC
Savoie Capital Chicago, Illinois $805M AUM 19.48% 1-Year Est. Return
BWA
Bordeaux Wealth Advisors Menlo Park, California $781M AUM 26.55% 1-Year Est. Return
CCP
Camelot Capital Partners Laguna Beach, California $686M AUM 163.55% 1-Year Est. Return

Camber Capital Management's Q3 2014 Portfolio in Review

As of Q3 2014, Camber Capital Management held 50 positions worth $1.06B, down 30% from $1.53B the previous quarter. Its ten largest holdings account for 54% of the portfolio.

Camber Capital Management withdrew a net $399M in Q3 2014, closing 13 positions and reducing 4 holdings. Its most notable exit was Elevance Health, an estimated $75.3M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 71% of assets, up from 62% a quarter earlier, followed by Consumer Discretionary.

Against the trend, Camber Capital Management opened a new position in GSK worth $55.2M.

  • Camber Capital Management's largest Q3 2014 buy was GSK: 960,000 shares worth $55.2M.
  • Camber Capital Management added most to Orthofix Medical in Q3 2014, an estimated $36.2M increase.
  • Camber Capital Management's biggest Q3 2014 reduction was Quest Diagnostics, cutting an estimated $37M.
  • Camber Capital Management fully exited Elevance Health in Q3 2014, selling an estimated $75.3M.
  • Camber Capital Management's ten largest holdings make up 54% of its $1.06B portfolio in Q3 2014.
  • Camber Capital Management opened 9 new positions and closed 13 in Q3 2014.
  • Camber Capital Management's portfolio value fell 30% quarter-over-quarter to $1.06B.

Based on Camber Capital Management's 13F filing for Q3 2014, filed 14 Nov 2014.